International Journal of Clinical Pharmacology, Therapy and Toxicology 1988-06-01

The bioavailability of methylepoxyproscillaridin (P35): a new semisynthetic cardiac glycoside.

J Bonelli, W Waginger, F Gazo

Index: Int. J. Clin. Pharmacol. Ther. Toxicol. 26(6) , 297-9, (1988)

Full Text: HTML

Abstract

The pharmacokinetic data of methylepoxyproscillaridin (3'-methyl-4'-5'-epoxyproscillaridin) (P35) after 1 mg i.v. or oral administration in two different galenic preparations (hard and soft gelatin capsules) in randomized succession were studied in 9 healthy volunteers, showing a bioavailability of 88 +/- 10.5% (soft gelatin capsule) and 81 +/- 12% (hard gelatin capsule). The half-life of P35 was calculated to be 80 +/- 13.3 h.